SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-021941
Filing Date
2023-08-03
Accepted
2023-08-03 16:15:07
Documents
13
Period of Report
2023-08-03
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20230803_8k.htm   iXBRL 8-K 112883
  Complete submission text file 0001437749-23-021941.txt   256227

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA dffn-20230803.xsd EX-101.SCH 3408
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dffn-20230803_def.xml EX-101.DEF 11423
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE dffn-20230803_lab.xml EX-101.LAB 15309
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dffn-20230803_pre.xml EX-101.PRE 11583
7 EXTRACTED XBRL INSTANCE DOCUMENT dffn20230803_8k_htm.xml XML 2575
Mailing Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902
Business Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

IRS No.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 231140200
SIC: 2834 Pharmaceutical Preparations